Biopsy-Based Transcriptomics Support Rejection Monitoring Through Repeated Kidney Allograft Biopsies.

ABSTRACT:

Introduction

Biopsy-based transcriptomics may detect subthreshold signals suspicious for rejection in histologically "rejection-free" biopsies, reflect antirejection treatment responses, and indicate gradual phenotyping of rejection in kidney allograft biopsies.

Methods

We investigated 80 "biopsy series" (baseline and corresponding follow-up biopsies) from 2018 to 2025, assessed by histopathology (Banff classification) and the Molecular Microscope Diagnostic System (MMDx).

Results

Baseline biopsies showed histological rejection, including partial antibody-mediated rejection (AMR) and borderline T-cell-mediated rejection (TCMR) in 55 of 80 cases (69%), with 55% molecular rejection confirmation. After a median of 9 months (interquartile range: 4-18), follow-up biopsies

SUBMITTER: Weidmann L 

PROVIDER: S-EPMC12266197 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature